Zai Lab Earnings Call Highlights Pipeline-Driven Upside
TipRanks (Mon, 17-Aug 8:07 PM ET)
Business Wire (Mon, 17-Aug 6:00 AM ET)
Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates
Business Wire (Thu, 6-Aug 6:30 AM ET)
Business Wire (Mon, 3-Aug 7:00 AM ET)
Business Wire (Wed, 22-Jul 7:30 AM ET)
Business Wire (Tue, 16-Jun 7:00 AM ET)
Business Wire (Mon, 8-Jun 8:34 PM ET)
Zai Lab Announces Changes to Senior Leadership Team
Business Wire (Thu, 21-May 6:09 PM ET)
Market Chameleon (Mon, 20-Apr 3:52 AM ET)
Zai Lab’s Dual-Targeting Strategy in Small Cell Lung Cancer: Potential to Set a New Standard
Market Chameleon (Wed, 1-Apr 3:32 AM ET)
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
Zai Lab Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol ZLAB.
As of August 19, 2026, ZLAB stock price climbed to $26.72 with 1,651,200 million shares trading.
ZLAB has a beta of 2.04, meaning it tends to be more sensitive to market movements. ZLAB has a correlation of 0.19 to the broad based SPY ETF.
ZLAB has a market cap of $3.00 billion. This is considered a Mid Cap stock.
Last quarter Zai Lab Limited - American Depositary Shares reported $106 million in Revenue and -$.46 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.19.
In the last 3 years, ZLAB traded as high as $44.34 and as low as $13.48.
The top ETF exchange traded funds that ZLAB belongs to (by Net Assets): IBB, CANC, SBIO, BBP, DFEM.
ZLAB has underperformed the market in the last year with a return of -25.1%, while SPY returned +20.7%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ZLAB shares. However, ZLAB has outperformed the market in the last 3 month and 2 week periods, returning +41.7% and +44.5%, while SPY returned +4.4% and -0.3%, respectively. This indicates ZLAB has been having a stronger performance recently.
ZLAB support price is $24.78 and resistance is $26.36 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ZLAB shares will trade within this expected range on the day.